Trial Profile
Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Utatrectinib (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- 14 Nov 2011 New trial record